Acrivon Therapeutics (NASDAQ: ACRV)
$7.25
(-6.1%)
-$0.47
Price as of June 14, 2024, 4:00 p.m. ET
Acrivon Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Acrivon Therapeutics Company Info
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of drug pipeline. Its AP3 is used to generate proprietary OncoSignature companion diagnostics to identify the patients who will benefit from the medicines. The company was founded by Peter Blume-Jensen and Kristina Masson on March 03, 2018 and is headquartered in Watertown, MA.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.